Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310446 · ClinicalTrials.gov registry record
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
A clinical trial of Colorectal Cancer, sponsored by Universal Diagnostics.
- Recruiting
- Registry status
- 6,500
- Enrollment target
- 1
- Study location
NCT07310446: Recruiting study of Colorectal Cancer, sponsored by Universal Diagnostics.
NCT07310446 is a study of Colorectal Cancer that is actively recruiting participants, run by Universal Diagnostics. The registered enrollment target is 6,500 participants, above the 1,528-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (325% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07310446, a study of Colorectal Cancer, is actively recruiting participants, sponsored by Universal Diagnostics.
- RECRUITING
- Registry status
- 6,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC from the diagnostic colonoscopy and clinical staging (cTMN) is available and are pr e- treatment, and patients who are at average risk of colorectal cancer and who are scheduled for routine colonoscopy examinations.
Primary Outcome
The primary objective of this study is to optimize and evaluate the performance, including sensitivity and specificity, of the preliminary cfDNA marker panel to detect CRC and APL.
Conditions Studied
Study Locations (1)
Illinois
- Gastroenterology and Internal Medicine Specialists - Lake Barrington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,500 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2027-07 |
What NCT07310446 shows while recruiting
NCT07310446 is an observational study that tracks outcomes without assigning an intervention. Its 6,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,528-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (325% higher).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07310446 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07310446 about?
NCT07310446 is a clinical study titled "Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance". This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC f...
What is the current status of trial NCT07310446?
This trial is currently recruiting. The enrollment target is 6,500 participants. The study started on 2023-07-31. Estimated completion is 2027-07.
What conditions does trial NCT07310446 study?
This clinical trial studies the following conditions: Colorectal Cancer.
Who is sponsoring clinical trial NCT07310446?
This trial is sponsored by Universal Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07310446 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07310446's enrollment target sits among peer trials
6,500 13th of 381 higher than 369 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00505245 · 6,500 participants
New Assessment System in Measuring Symptom Distress in Cancer Patients
- NCT06821009 · 6,500 participants · NA
Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI